Gentamicin, with or without the concomitant administration of carbenicillin, is widely used in the treatment of hospital-acquired, gramnegative bacillary infection, including those caused by Pseudomonas aeruginosa. Gentamicin is far from an ideal antimicrobial agent. Peak serum levels after administration of recommended doses may barely exceed the inhibitory concentrations for frequently isolated gram-negative bacilli, whereas the administration of larger doses may lead to significant toxicity. Further, the emergence of isolates with high-level resistance to gentamicin has been well documented (3) . Accordingly, the search continues for new aminoglycoside antibiotics that might exhibit greater antibacterial activity and.less toxicity. Netilmicin (Sch 20569), an agent differing from sisomicin by the presence of an ethyl group at the 1-N position of the deoxystreptamine moiety, has recently been provided for in vitro work. Initial animal toxicity studies indicated that this agent may be less oto-and nephrotoxic than gentamicin (5) . Our study compares the in vitro activity of netilmicin with those of gentamicin, tobramycin, and amikacin against recent isolates of P. aeruginosa and various Enterobacteriaceae. In addition, the potentiation of the activity of the four aminoglycosides against P. aeruginosa by carbenicillin was evaluated.
MATERIALS AND METHODS Bacterial isolates. Two hundred and forty-two clinical isolates were obtained from the diagnostic microbiology laboratory of the Royal Victoria Hospital. These isolates included Escherichia coli (35), Klebsiella pneumoniae (36), Enterobacter (36), Proteus mirabilis (37), indole-positive Proteus (25), Providencia stuartii (10), and P. aeruginosa (63). The identity of all isolates was confirmed by standard methods. Not more than one isolate of a given species per patient was included.
Antibiotics. Gentamicin sulfate and netilmicin sulfate were supplied by the Schering Corp. Amikacin was supplied by Bristol Laboratories, tobramycin by Eli Lilly and Co., and carbenicillin disodium by Ayerst Laboratories. Antibiotic stock solutions were stored at -70°C.
Agar dilution susceptibility. Minimal inhibitory concentrations (MIC) were determined for all isolates by an agar dilution method in Mueller-Hinton agar. Parallel series of antibiotic-containing plates were inoculated for each antibiotic by a multiple inoculator apparatus (8) MICs of the four aminoglycosides tested against the large inocula ofE. coli, K. pneumoniae, and Enterobacter are shown in Table 1 . The in vitro activities of netilmicin and gentamicin were almost identical, inhibiting 90% or more of isolates at a concentration of 3.1 ug/ml. A small percentage of K. pneumoniae and Enterobacter (3 to 5%) had netilmicin or gentamicin MICs 2 12.5 ,ug/ml. Tobramycin inhibited all E. coli and K. pneumoniae at a concentration of 1.6 /ig/ml, but about 3% of Enterobacter isolates had MICs -12.5 jug/ml. Amikacin inhibited all isolates at a concentration of 12.5 ,zg/ml or less.
The MIC values of the four agents for isolates of P. mirabilis, indole-positive Proteus, and P. stuartii are presented in Table 2 . In each instance netilmicin and gentamicin demonstrated similar activity. Netilmicin inhibited 70.3% ofP. mirabilis and 80% of indole-positive Proteus at a concentration of 3.1 ug/ml, compared to 78.4 and 76%, respectively, inhibited by gentamicin. Tobramycin showed greater activity, inhibiting 86.5% of P. mirabilis and 92.0% of indole-positive Proteus at a concentration of 3.1 ,mg/ml. None of these three agents showed significant activity against P. stuartii. Amikacin was highly active against these isolates, inhibiting 83.7% of P. mirabilis, 96% of indole-positive Proteus, and all P. stuartii at a concentration of 12.5 ,ug/ml.
Almost complete cross-resistance was exhibited to netilmicin by isolates ofEnterobacteriaceae highly resistant to gentamicin (MIC 2 25 gg/ml). One of the 14 such isolates had a netilmicin MIC of 6.3 ,ug/ml; all other MIC values were .12.5 ,ug/ml (Table 3) . Tobramycin also showed little activity against most gentamicin-resistant isolates but amikacin was highly active, inhibiting 10 isolates at a concentration of 12.5 gg/ml. The four amikacin-resistant P. mirabilis isolates were also resistant to the other agents tested by this method. Netilmicin exhibited little activity against P. aeruginosa when tested by the agar dilution method, inhibiting only 7.9% of isolates at a concentration of 3.1 ,ug/ml compared to 22.2% inhibited by gentamicin (Fig. 1) . Tobramycin was the most active anti-Pseudomonas agent; 87.3% of isolates had MICs of 3.1 ,ug/ml or less. Amikacin inhibited 68.3% ofP. aeruginosa at a concentration of 12.5 ,ug/ml. Of 18 gentamicinresistant P. aeruginosa (MIC -25 ,ug/ml), none had a netilmicin MIC lower than 25 ,ug/ ml. In contrast, tobramycin inhibited 11 such isolates at 3.1 ug/ml. Only one gentamicin- resistant P. aeruginosa was inhibited by amikacin at a concentration of 12.5 ug/ml.
Broth dilution susceptibility tests. The MIC of the four aminoglycosides was determined in MHB for 20 isolates each of Enterobacteriaceae and P. aeruginosa. Eighteen of the 20 Enterobacteriaceae and all 20 P. aeruginosa selected had gentamicin MICs 2 12.5 ,ug/ml by the agar dilution method.
The correlations between MICs determined in agar or broth for Enterobacteriaceae are shown in Fig. 2 20 Enterobacteriaceae were -6.3 ,tg/ml; when retested in broth, only 8 showed MICs of 3.1 ,ug/ml or less. Three of the four P. mirabilis isolates that exhibited high-level resistance to the four anti-biotics by the agar dilution method (Table 3) were tested by broth dilution. All had netilmicin, gentamicin, and tobramycin MICs c 3.1 ,ug/ml and an amikacin MIC c 12.5 ,ug/ml.
Twelve isolates of Enterobacteriaceae had gentamicin MICs -6.3 ug/ml by tube dilution (Table 4) . Only one of these isolates had a netilmicin MIC < 6.3 jig/ml, and only two had a tobramycin MIC < 6.3 ,ug/ml. In contrast, the amikacin MIC of 10/12 gentamicin-resistant isolates was <12.5 ,.g/ml.
The relationships between the MIC of the agents determined by agar dilution and those determined by broth dilution for P. aeruginosa are shown in Fig. 3 cases, a fourfold or greater decrease in the MIC as determined in broth was noted: this occurred for netilmicin and gentamicin with 17 of 20 isolates, for tobramycin with 14 of 20 isolates, and for amikacin with 18 of 20 isolates. The numbers of isolates out of 20 tested with broth dilution MICs > 3.1 ug/ml for netilmicin, gentamicin, and tobramycin were 7, 4, and 1, respectively. Only 1 of the 20 isolates tested had an amikacin MIC > 6.3 ,ug/ml under the same conditions.
Comparison of MBC with MIC for the 40 isolates evaluated showed that in only three instances was there a greater than fourfold increase in MBC, over MIC for netilmicin and gentamicin, whereas 7 of 40 isolates had tobramycin or amikacin MBCs fourfold or more greater than the corresponding MIC value.
Potentiation of aminoglycoside activity by carbenicillin. Eighteen of the 20 P. aeruginosa isolates whose MIC to the aminoglycosides had been determined by the tube dilution method were resistant to 50 ,ug of carbenicillin per ml alone in MHB. The effect of added carbenicillin (50 p.g/ml) on the MICs of the four aminoglycosides for these 18 isolates is shown in Fig. 4 .
Netilmicin and gentamicin MICs determined in the presence of carbenicillin were lowered to one-quarter or less of the value obtained in its absence for 15 of 18 isolates. The netilmicin MICs measured in the presence of carbenicillin were 3.1 ,Mg/ml or less for 16 of 18 isolates; two remained resistant, with MICs of 50 and >100 ,g/ml, respectively. Similar results were obtained with gentamicin; MICs of 15 of 18 isolates were <3.1 ,ug/ml. In no instance was there evidence of drug antagonism.
A similar fourfold or greater reduction of MIC was observed in 9 of 18 isolates for tobramycin and 16 of 18 isolates for amikacin. DISCUSSION In contrast to previously published data (5), we found netilmicin provided no advantage in antimicrobial activity over gentamicin for either P. aeruginosa or Enterobacteriaceae. Nearly complete cross-resistance to netilmicin was encountered with isolates resistant to gentamicin when tested in solid or liquid media. Netilmicin was less active than gentamicin against isolates of P. aeruginosa and P. stuartii. Netilmicin exhibits typical aminoglycoside characteristics, such as little effect of inoculum size on MIC, relatively small gap between MIC and MBC, and the potentiation of its anti-Pseudomonas activity when combined with carbenicillin. Major discrepancies between MIC values determined in agar as opposed to those determined in broth for P. aeruginosa, well described for other aminoglycosides, are also found with netilmicin. These discrepancies have been attributed in the case of P. aeruginosa to a cell wall-stabilizing effect of high concentrations of divalent cations, especially 1, 2, 7) . Supporting this is the fact that markedly increased binding and presumably cell wall penetration of 3H-labeled gentamicin to Pseudomonas occurs in media with low divalent ion concentrations (6) . In addition, the "protective" effect of high divalent cation concentrations is lost when the organism being tested is a carbenicillin-induced spheroplast in hypertonic medium (9) . Previous investigators have concluded that the divalent cation concentration in the medium has little or no effect in susceptibility tests of Enterobacteriaceae (2, 4, 9) . These conclusions, however, rest upon the testing of relatively small numbers of isolates. We found that, depending upon which aminoglycoside was used, between 15 and 40% of the isolates of Enterobacteriaceae exhibited fourfold or greater diminutions of MIC when tested in broth as compared to agar. For some Enterobacteriaceae differences in media may create as significant a problem in interpretation of in vitro susceptibility test results, as already exists for P. aeruginosa.
If further studies in experimental animals and humans demonstrate that netilmicin indeed possesses less toxic potential than other currently available aminoglycoside antibiotics, this agent may become a useful therapeutic tool.
